Showing 4371-4380 of 6983 results for "".
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- Bioré Skincare Partners with Girl Uphttps://practicaldermatology.com/news/bior-skincare-partners-with-girl-up/2458081/To celebrate the launch of their new Limited Edition Deep Cleansing Pore Strips, Bioré® Skincare is partnering with Girl Up™, a United Nations Foundation campaign. Girl Up mobilizes girls and women across the globe to raise awareness and funds for United Nations prog
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- Early Use of CO2 Lasers on Surgical Scars Bests Silicone Gel Treatmenthttps://practicaldermatology.com/news/early-use-of-co2-lasers-on-surgical-scars-bests-silicone-gel-treatment/2458112/Early treatment of surgical scars with a super-pulsed fractional C02 laser shows promise, new research suggests. The study, which appears in Lasers in Surgery and Medicine (LSM), found that laser treatment of
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Dr. Jacqualyn Fouse Named Executive Chairman of Dermavanthttps://practicaldermatology.com/news/dr-jacqualyn-fouse-named-executive-chairman-of-dermavent/2458127/Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory approval, commercializing three investigational d